Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study

Migraine and Headache

Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study

Cephalalgia

Overeem LH, Peikert A, Hofacker MD, Kamm K, Ruscheweyh R, Gendolla A, Raffaelli B, Reuter U, Neeb L

doi: 10.1177/03331024211048765

Migraine and Headache

A prospective pilot study of the effect on catecholamines of mindfulness training vs pharmacological prophylaxis in patients with chronic migraine and medication overuse headache

Cephalalgia.

Grazzi L, Raggi A, D'Amico D, Sansone E, Leonardi M, Andrasik F, Gucciardi A, Guido D, D'Andrea G

doi: 10.1177/0333102418801584.

Migraine and Headache

Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment - a real-life cohort study

Cephalalgia

Gantenbein AR, Agosti R, Gobbi C, Flügel D, Schankin CJ, Viceic D, Zecca C, Pohl H

doi: 10.1177/03331024211014616

COMMENTED

Migraine and Headache

Associations Between Migraine and Type 2 Diabetes in Women: Findings From the E3N Cohort Study

JAMA Neurol.

Fagherazzi G, El Fatouhi D, Fournier A, Gusto G, Mancini FR, Balkau B, Boutron-Ruault MC, Kurth T, Bonnet F

doi: 10.1001/jamaneurol.

Anxiety and Depression

The incidence and predictors of depressive and anxiety symptoms in older adults with vision impairment: a longitudinal prospective cohort study

Ophthalmic Physiol Opt.

Heesterbeek TJ, van der Aa HPA, van Rens GHMB, Twisk JWR, van Nispen RMA

doi: 10.1111/opo.12388.

Migraine and Headache

Calcitonin Gene-Related Peptide Modulators - The History and Renaissance of a New Migraine Drug Class

Headache.

Hargreaves R, Olesen J

doi: 10.1111/head.13510.

Parkinson’s Disease

Parkinson's disease: evolution of cognitive impairment and CSF Aβ1-42 profiles in a prospective longitudinal study

J Neurol Neurosurg Psychiatry.

Lerche S, Wurster I, Röben B, Machetanz G, Zimmermann M, Bernhard F, Stransky E, Deuschle C, Schulte C, Hansson O, Zetterberg H, Gasser T, Berg D, Maetzler W, Brockmann K

doi: 10.1136/jnnp-2018-318956.

RECOMMENDED

Migraine and Headache

Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study)

Cephalalgia.

Brandes JL, Klise S, Krege JH, Case M, Khanna R, Vasudeva R, Raskin J, Pearlman EM, Kudrow D

doi: 10.1177/0333102419864132.

Stroke

Predicting Longitudinal Progression in Functional Mobility After Stroke: A Prospective Cohort Study.

Stroke.

Buvarp D, Rafsten L, Sunnerhagen KS

doi: 10.1161/STROKEAHA.

Related content

Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study

A prospective pilot study of the effect on catecholamines of mindfulness training vs pharmacological prophylaxis in patients with chronic migraine and medication overuse headache

Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment - a real-life cohort study

Associations Between Migraine and Type 2 Diabetes in Women: Findings From the E3N Cohort Study

The incidence and predictors of depressive and anxiety symptoms in older adults with vision impairment: a longitudinal prospective cohort study

Calcitonin Gene-Related Peptide Modulators - The History and Renaissance of a New Migraine Drug Class

Parkinson's disease: evolution of cognitive impairment and CSF Aβ1-42 profiles in a prospective longitudinal study

Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study)

Predicting Longitudinal Progression in Functional Mobility After Stroke: A Prospective Cohort Study.